BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 25370206)

  • 1. An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naïve to phosphodiesterase 5 inhibitor therapy.
    Bai WJ; Li HJ; Dai YT; He XY; Huang YR; Liu JH; Sorsaburu S; Ji C; Jin JJ; Wang XF
    Asian J Androl; 2015; 17(1):61-7. PubMed ID: 25370206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction.
    Bai WJ; Li HJ; Jin JJ; Xu WP; Sebastian S; Wang XF
    Asian J Androl; 2017; 19(4):500-504. PubMed ID: 27101805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy.
    Eardley I; Mirone V; Montorsi F; Ralph D; Kell P; Warner MR; Zhao Y; Beardsworth A
    BJU Int; 2005 Dec; 96(9):1323-32. PubMed ID: 16287454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction.
    Li HJ; Bai WJ; Dai YT; Xu WP; Wang CN; Li HZ
    Asian J Androl; 2016; 18(5):773-9. PubMed ID: 26459780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study.
    Dean J; Hackett GI; Gentile V; Pirozzi-Farina F; Rosen RC; Zhao Y; Warner MR; Beardsworth A
    J Sex Med; 2006 Jul; 3(4):650-661. PubMed ID: 16839321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of tadalafil in men with erectile dysfunction naïve to phosphodiesterase 5 inhibitor therapy compared with prior responders to sildenafil citrate.
    Broderick GA; Donatucci CF; Hatzichristou D; Torres LO; Valiquette L; Zhao Y; Loughney K; Sides GD; Ahuja S
    J Sex Med; 2006 Jul; 3(4):668-675. PubMed ID: 16839323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
    Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
    J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors.
    Tolrà JR; Campaña JMC; Ciutat LF; Miranda EF
    J Sex Med; 2006 Sep; 3(5):901-909. PubMed ID: 16942534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference.
    Ströberg P; Murphy A; Costigan T
    Clin Ther; 2003 Nov; 25(11):2724-37. PubMed ID: 14693300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of tadalafil once daily in men with erectile dysfunction who demonstrated previous partial responses to as-needed sildenafil, tadalafil, or vardenafil.
    Kim E; Seftel A; Goldfischer E; Baygani S; Burns P
    Curr Med Res Opin; 2015 Feb; 31(2):379-89. PubMed ID: 25455432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, parallel study to assess the efficacy and safety of once-a-day tadalafil in men with erectile dysfunction who are naïve to PDE5 inhibitors.
    Montorsi F; Aversa A; Moncada I; Perimenis P; Porst H; Barker C; Shane MA; Sorsaburu S
    J Sex Med; 2011 Sep; 8(9):2617-24. PubMed ID: 21707928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of two dosing regimens of tadalafil and patterns of sexual activity in men with diabetes mellitus and erectile dysfunction: Scheduled use vs. on-demand regimen evaluation (SURE) study in 14 European countries.
    Buvat J; van Ahlen H; Schmitt H; Chan M; Kuepfer C; Varanese L
    J Sex Med; 2006 May; 3(3):512-20. PubMed ID: 16681477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis.
    Gong B; Ma M; Xie W; Yang X; Huang Y; Sun T; Luo Y; Huang J
    Int Urol Nephrol; 2017 Oct; 49(10):1731-1740. PubMed ID: 28741090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the long-term safety and effectiveness of tadalafil once daily in Chinese men with erectile dysfunction: interim results of a multicenter, randomized, open-label trial.
    Jiang H; Zhao LM; Lin HC; Yan S; Liu JH; Zhu ZH; Luo JD; Dai YT; Li FB; Lou Y; Zhang ZC
    Asian J Androl; 2018; 20(6):587-592. PubMed ID: 30004039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tadalafil is efficacious and well tolerated in the treatment of erectile dysfunction (ED) in men over 65 years of age: results from Multiple Observations in Men with ED in National Tadalafil Study in the United States.
    Sharlip ID; Shumaker BP; Hakim LS; Goldfischer E; Natanegara F; Wong DG
    J Sex Med; 2008 Mar; 5(3):716-25. PubMed ID: 18304286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study.
    Hatzimouratidis K; Buvat J; Büttner H; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    Int J Impot Res; 2014; 26(6):223-9. PubMed ID: 24784894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study.
    Rubio-Aurioles E; Porst H; Eardley I; Goldstein I
    J Sex Med; 2006 Nov; 3(6):1037-1049. PubMed ID: 17100937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.